Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administratio...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2021-05, Vol.72 (9), p.1585-1593 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1593 |
|---|---|
| container_issue | 9 |
| container_start_page | 1585 |
| container_title | Clinical infectious diseases |
| container_volume | 72 |
| creator | Dolo, Housseini Coulibaly, Yaya I Sow, Moussa Dembélé, Massitan Doumbia, Salif S Coulibaly, Siaka Y Sangare, Moussa B Dicko, Ilo Diallo, Abdallah A Soumaoro, Lamine Coulibaly, Michel E Diarra, Dansine Colebunders, Robert Nutman, Thomas B Walker, Martin Basáñez, Maria-Gloria |
| description | Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.
The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years).
In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was |
| doi_str_mv | 10.1093/cid/ciaa318 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8096229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2382660855</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3322-15a08c1127fde69f85a526c3b98bbbaaeb1563a9676141622088f0478f79686a3</originalsourceid><addsrcrecordid>eNpVkcFOAyEQhonRaK2evBuOJroKS2HZi4k2rZrUeFDPZJayFmWXCm2TPpLP0RcTbTV6IJDMN98M-RE6ouSckpJdaDtOB4BRuYU6lLMiE7yk2-lNuMx6ksk9tB_jKyGUSsJ30R7LcyKKgnVQfDTBO_9iNTg8WICbw8z6FvsaP7R64rUJyR1txNCO8WjZTCcJ0HhoHYR1YeBsY9t1m23xbGLwNbz5pfluGYJbfTSrDzz02p7he3D2AO3U4KI53Nxd9DwcPPVvs9HDzV3_apRplhbMKAciNaV5UY-NKGvJgedCs6qUVVUBmIpywaAUhaA9KtKXpKxJr5B1UQopgHXR5do7nVeNGWvTzgI4NQ22gbBUHqz6X2ntRL34hZKkTLoyCU42guDf5ybOVGOjNs5Ba_w8qpzJXAgiOU_o6RrVwccYTP07hhL1FZNKMalNTIk-_rvZL_uTC_sEgMuRkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382660855</pqid></control><display><type>article</type><title>Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Dolo, Housseini ; Coulibaly, Yaya I ; Sow, Moussa ; Dembélé, Massitan ; Doumbia, Salif S ; Coulibaly, Siaka Y ; Sangare, Moussa B ; Dicko, Ilo ; Diallo, Abdallah A ; Soumaoro, Lamine ; Coulibaly, Michel E ; Diarra, Dansine ; Colebunders, Robert ; Nutman, Thomas B ; Walker, Martin ; Basáñez, Maria-Gloria</creator><creatorcontrib>Dolo, Housseini ; Coulibaly, Yaya I ; Sow, Moussa ; Dembélé, Massitan ; Doumbia, Salif S ; Coulibaly, Siaka Y ; Sangare, Moussa B ; Dicko, Ilo ; Diallo, Abdallah A ; Soumaoro, Lamine ; Coulibaly, Michel E ; Diarra, Dansine ; Colebunders, Robert ; Nutman, Thomas B ; Walker, Martin ; Basáñez, Maria-Gloria</creatorcontrib><description>Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.
The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years).
In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was <2% in ≤14 year-olds, and 16% in ≥40 year-olds. Wb123 seropositivity was <2% in ≤39 year-olds, reaching 3% in ≥40 year-olds.
Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip polymerase chain reaction tested and followed up.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa318</identifier><identifier>PMID: 32206773</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Elephantiasis, Filarial - drug therapy ; Elephantiasis, Filarial - epidemiology ; Elephantiasis, Filarial - prevention & control ; Humans ; Ivermectin - therapeutic use ; Major and Commentaries ; Mali - epidemiology ; Middle Aged ; Onchocerciasis - drug therapy ; Onchocerciasis - epidemiology ; Onchocerciasis - prevention & control ; Seroepidemiologic Studies ; Young Adult</subject><ispartof>Clinical infectious diseases, 2021-05, Vol.72 (9), p.1585-1593</ispartof><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3322-15a08c1127fde69f85a526c3b98bbbaaeb1563a9676141622088f0478f79686a3</citedby><cites>FETCH-LOGICAL-c3322-15a08c1127fde69f85a526c3b98bbbaaeb1563a9676141622088f0478f79686a3</cites><orcidid>0000-0002-1919-1340 ; 0000-0002-4234-3488 ; 0000-0001-5031-3361</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32206773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dolo, Housseini</creatorcontrib><creatorcontrib>Coulibaly, Yaya I</creatorcontrib><creatorcontrib>Sow, Moussa</creatorcontrib><creatorcontrib>Dembélé, Massitan</creatorcontrib><creatorcontrib>Doumbia, Salif S</creatorcontrib><creatorcontrib>Coulibaly, Siaka Y</creatorcontrib><creatorcontrib>Sangare, Moussa B</creatorcontrib><creatorcontrib>Dicko, Ilo</creatorcontrib><creatorcontrib>Diallo, Abdallah A</creatorcontrib><creatorcontrib>Soumaoro, Lamine</creatorcontrib><creatorcontrib>Coulibaly, Michel E</creatorcontrib><creatorcontrib>Diarra, Dansine</creatorcontrib><creatorcontrib>Colebunders, Robert</creatorcontrib><creatorcontrib>Nutman, Thomas B</creatorcontrib><creatorcontrib>Walker, Martin</creatorcontrib><creatorcontrib>Basáñez, Maria-Gloria</creatorcontrib><title>Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.
The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years).
In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was <2% in ≤14 year-olds, and 16% in ≥40 year-olds. Wb123 seropositivity was <2% in ≤39 year-olds, reaching 3% in ≥40 year-olds.
Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip polymerase chain reaction tested and followed up.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Elephantiasis, Filarial - drug therapy</subject><subject>Elephantiasis, Filarial - epidemiology</subject><subject>Elephantiasis, Filarial - prevention & control</subject><subject>Humans</subject><subject>Ivermectin - therapeutic use</subject><subject>Major and Commentaries</subject><subject>Mali - epidemiology</subject><subject>Middle Aged</subject><subject>Onchocerciasis - drug therapy</subject><subject>Onchocerciasis - epidemiology</subject><subject>Onchocerciasis - prevention & control</subject><subject>Seroepidemiologic Studies</subject><subject>Young Adult</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFOAyEQhonRaK2evBuOJroKS2HZi4k2rZrUeFDPZJayFmWXCm2TPpLP0RcTbTV6IJDMN98M-RE6ouSckpJdaDtOB4BRuYU6lLMiE7yk2-lNuMx6ksk9tB_jKyGUSsJ30R7LcyKKgnVQfDTBO_9iNTg8WICbw8z6FvsaP7R64rUJyR1txNCO8WjZTCcJ0HhoHYR1YeBsY9t1m23xbGLwNbz5pfluGYJbfTSrDzz02p7he3D2AO3U4KI53Nxd9DwcPPVvs9HDzV3_apRplhbMKAciNaV5UY-NKGvJgedCs6qUVVUBmIpywaAUhaA9KtKXpKxJr5B1UQopgHXR5do7nVeNGWvTzgI4NQ22gbBUHqz6X2ntRL34hZKkTLoyCU42guDf5ybOVGOjNs5Ba_w8qpzJXAgiOU_o6RrVwccYTP07hhL1FZNKMalNTIk-_rvZL_uTC_sEgMuRkw</recordid><startdate>20210504</startdate><enddate>20210504</enddate><creator>Dolo, Housseini</creator><creator>Coulibaly, Yaya I</creator><creator>Sow, Moussa</creator><creator>Dembélé, Massitan</creator><creator>Doumbia, Salif S</creator><creator>Coulibaly, Siaka Y</creator><creator>Sangare, Moussa B</creator><creator>Dicko, Ilo</creator><creator>Diallo, Abdallah A</creator><creator>Soumaoro, Lamine</creator><creator>Coulibaly, Michel E</creator><creator>Diarra, Dansine</creator><creator>Colebunders, Robert</creator><creator>Nutman, Thomas B</creator><creator>Walker, Martin</creator><creator>Basáñez, Maria-Gloria</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1919-1340</orcidid><orcidid>https://orcid.org/0000-0002-4234-3488</orcidid><orcidid>https://orcid.org/0000-0001-5031-3361</orcidid></search><sort><creationdate>20210504</creationdate><title>Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali</title><author>Dolo, Housseini ; Coulibaly, Yaya I ; Sow, Moussa ; Dembélé, Massitan ; Doumbia, Salif S ; Coulibaly, Siaka Y ; Sangare, Moussa B ; Dicko, Ilo ; Diallo, Abdallah A ; Soumaoro, Lamine ; Coulibaly, Michel E ; Diarra, Dansine ; Colebunders, Robert ; Nutman, Thomas B ; Walker, Martin ; Basáñez, Maria-Gloria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3322-15a08c1127fde69f85a526c3b98bbbaaeb1563a9676141622088f0478f79686a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Elephantiasis, Filarial - drug therapy</topic><topic>Elephantiasis, Filarial - epidemiology</topic><topic>Elephantiasis, Filarial - prevention & control</topic><topic>Humans</topic><topic>Ivermectin - therapeutic use</topic><topic>Major and Commentaries</topic><topic>Mali - epidemiology</topic><topic>Middle Aged</topic><topic>Onchocerciasis - drug therapy</topic><topic>Onchocerciasis - epidemiology</topic><topic>Onchocerciasis - prevention & control</topic><topic>Seroepidemiologic Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dolo, Housseini</creatorcontrib><creatorcontrib>Coulibaly, Yaya I</creatorcontrib><creatorcontrib>Sow, Moussa</creatorcontrib><creatorcontrib>Dembélé, Massitan</creatorcontrib><creatorcontrib>Doumbia, Salif S</creatorcontrib><creatorcontrib>Coulibaly, Siaka Y</creatorcontrib><creatorcontrib>Sangare, Moussa B</creatorcontrib><creatorcontrib>Dicko, Ilo</creatorcontrib><creatorcontrib>Diallo, Abdallah A</creatorcontrib><creatorcontrib>Soumaoro, Lamine</creatorcontrib><creatorcontrib>Coulibaly, Michel E</creatorcontrib><creatorcontrib>Diarra, Dansine</creatorcontrib><creatorcontrib>Colebunders, Robert</creatorcontrib><creatorcontrib>Nutman, Thomas B</creatorcontrib><creatorcontrib>Walker, Martin</creatorcontrib><creatorcontrib>Basáñez, Maria-Gloria</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dolo, Housseini</au><au>Coulibaly, Yaya I</au><au>Sow, Moussa</au><au>Dembélé, Massitan</au><au>Doumbia, Salif S</au><au>Coulibaly, Siaka Y</au><au>Sangare, Moussa B</au><au>Dicko, Ilo</au><au>Diallo, Abdallah A</au><au>Soumaoro, Lamine</au><au>Coulibaly, Michel E</au><au>Diarra, Dansine</au><au>Colebunders, Robert</au><au>Nutman, Thomas B</au><au>Walker, Martin</au><au>Basáñez, Maria-Gloria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-05-04</date><risdate>2021</risdate><volume>72</volume><issue>9</issue><spage>1585</spage><epage>1593</epage><pages>1585-1593</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.
The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years).
In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was <2% in ≤14 year-olds, and 16% in ≥40 year-olds. Wb123 seropositivity was <2% in ≤39 year-olds, reaching 3% in ≥40 year-olds.
Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip polymerase chain reaction tested and followed up.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>32206773</pmid><doi>10.1093/cid/ciaa318</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1919-1340</orcidid><orcidid>https://orcid.org/0000-0002-4234-3488</orcidid><orcidid>https://orcid.org/0000-0001-5031-3361</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2021-05, Vol.72 (9), p.1585-1593 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8096229 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Child Child, Preschool Elephantiasis, Filarial - drug therapy Elephantiasis, Filarial - epidemiology Elephantiasis, Filarial - prevention & control Humans Ivermectin - therapeutic use Major and Commentaries Mali - epidemiology Middle Aged Onchocerciasis - drug therapy Onchocerciasis - epidemiology Onchocerciasis - prevention & control Seroepidemiologic Studies Young Adult |
| title | Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A32%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serological%20Evaluation%20of%20Onchocerciasis%20and%20Lymphatic%20Filariasis%20Elimination%20in%20the%20Bakoye%20and%20Fal%C3%A9m%C3%A9%20Foci,%20Mali&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Dolo,%20Housseini&rft.date=2021-05-04&rft.volume=72&rft.issue=9&rft.spage=1585&rft.epage=1593&rft.pages=1585-1593&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa318&rft_dat=%3Cproquest_pubme%3E2382660855%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2382660855&rft_id=info:pmid/32206773&rfr_iscdi=true |